News Release

 

Back
 

Two AmerisourceBergen Directors Re-Elected at Annual Meeting of Stockholders; Richard C. Gozon Succeeds James R. Mellor as Chairman of the Board

02/09/06

PHILADELPHIA--(BUSINESS WIRE)--Feb. 9, 2006--At the AmerisourceBergen Corporation (NYSE:ABC) annual meeting of stockholders, held today in Philadelphia, Company stockholders re-elected two directors: Richard C. Gozon and J. Lawrence Wilson. In addition, stockholders approved the amendment to the certificate of incorporation to increase the number of shares of common stock that the Company is authorized to issue; approved the amendments to the Company's 2002 Management Stock Incentive Plan; and ratified the appointment of Ernst & Young as the Company's independent registered public accounting firm for the 2006 fiscal year.

During the meeting stockholders also heard a review of the Company's activities and outlook from Chief Executive Officer, R. David Yost.

As previously announced, James R. Mellor, Chairman of AmerisourceBergen's Board of Directors, retired at the conclusion of today's meeting, and is succeeded by Mr. Gozon.

Mr. Gozon, 67, has been a director of the Company since August 2001. Prior to that, he was a director of AmeriSource Health Corporation from 1994 to August 2001. He was Executive Vice President of Weyerhaeuser Company and Chairman of North Pacific Paper Company from June 1994 until his retirement in 2002. Mr. Gozon is also lead director of Triumph Group, Inc., a director of UGI Corporation and AmeriGas Partners, L.P. and a member of the Board of Trustees of Thomas Jefferson University.

Mr. Wilson, 69, has been a director of the Company since August 2001. Prior to that, he was a director of AmeriSource Health Corporation from January 2000 to August 2001. He was Chairman and Chief Executive Officer of Rohm and Haas Company from 1988 until his retirement in 1999. Mr. Wilson is also a director of Cummins Inc., MeadWestvaco Corporation and the Vanguard Group of Investment Companies.

The AmerisourceBergen Board of Directors is composed of nine directors.

About AmerisourceBergen

AmerisourceBergen (NYSE:ABC) is one of the world's largest pharmaceutical services companies serving the United States and Canada. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to pharmacy services for skilled nursing and assisted living facilities, reimbursement and pharmaceutical consulting services, and physician education. With more than $54 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 13,000 people. AmerisourceBergen is ranked #23 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. Forward-looking statements may include statements addressing AmerisourceBergen's future financial and operating results and the benefits, efficiencies and savings to be derived from the Company's integration plans to consolidate its distribution network.

The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer or supplier relationships; customer defaults or insolvencies; changes in customer mix; supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes; changes in U.S. government policies (including reimbursement changes arising from the Medicare Modernization Act); market interest rates; operational or control issues arising from AmerisourceBergen's outsourcing of information technology activities; success of the Pharmaceutical Distribution segment's ability to transition its business model to fee-for-service; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar - Canadian dollar exchange rate; economic, business, competitive and/or regulatory developments in Canada; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; and other economic, business, competitive, legal, regulatory and/or operational factors affecting the business of AmerisourceBergen generally.

More detailed information about these and other risk factors is set forth in AmerisourceBergen's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2005.

AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward looking statements whether as a result of new information, future events or otherwise.


    CONTACT: AmerisourceBergen Corporation, Valley Forge
             Michael N. Kilpatric, 610-727-7118
             mkilpatric@amerisourcebergen.com

    SOURCE: AmerisourceBergen Corporation

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More